HALOZYME THERAPEUTICS INC (HALO)       38.64  +0.06 (+0.16%)

Halozyme to Participate in the 2022 Wells Fargo Healthcare Conference

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is...

Halozyme Therapeutics Becomes Oversold (HALO)

Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Million of Convertible Senior Notes due 2028

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today...

Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2028

The Company plans to purchase up to $200 million worth of shares concurrently with, or shortly after, the pricing of the offeringSAN DIEGO, Aug. 1...

Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2028

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery and...

Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche's Phase III IMscin001 study evaluating a subcutaneous (SC)...

Halozyme to Report Second Quarter 2022 Financial and Operating Results

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2022 financial and operating results...

First Week of HALO March 2023 Options Trading

XRP Now Buys You the Least Amount of Halozyme Therapeutics in the Past Year

Halozyme Therapeutics Larger Than S&P 500 Component Bath & Body Works

7 Biotech Stocks With Key Catalysts Coming in July

Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth.

Halozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is...

First Week of July 15th Options Trading For Halozyme Therapeutics

HALO Crosses Below Key Moving Average Level

Halozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2022 on May 10 at 4:30 p.m....

SHAREHOLDER ALERT: Weiss Law Investigates Antares Pharma, Inc.

/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Antares Pharma, Inc....

Why Is Sierra Oncology (SRRA) Stock Up Today?

Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring.

Why Is Antares Pharma (ATRS) Stock Up Today?

Antares Pharma (ATRS) stock is rocketing higher on Wednesday after the company reached an acquisition agreement with Halozyme (HALO).

Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares

GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying.